Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18F]UCB-H [0.03%]
使用正电子发射断层显像和[18F]UCB-H测量脑突触囊泡蛋白2A
Mohamed Ali Bahri,Alain Plenevaux,Joël Aerts et al.
Mohamed Ali Bahri et al.
Introduction: Brain distribution of synaptic vesicle protein 2A was measured with fluorine-18 UCB-H ([18F]UCB-H) and positron emission tomography (PET). M...
Midlife anticholinergic drug use, risk of Alzheimer's disease, and brain atrophy in community-dwelling older adults [0.03%]
中年时使用抗胆碱药物与社区老年人患阿尔茨海默病的风险和脑萎缩的关系
Yi-Fang Chuang,Palchamy Elango,Christopher E Gonzalez et al.
Yi-Fang Chuang et al.
Introduction: We examined how long-term anticholinergic (AC) drug use beginning at midlife affects risk of Alzheimer's disease (AD) and rates of brain atrophy in cognitively normal older adults. ...
Combined mnemonic strategy training and high-definition transcranial direct current stimulation for memory deficits in mild cognitive impairment [0.03%]
结合助记策略训练和高清晰经颅直流电刺激改善轻度认知障碍患者的记忆缺损
Benjamin M Hampstead,Krishnankutty Sathian,Marom Bikson et al.
Benjamin M Hampstead et al.
Introduction: Memory deficits characterize Alzheimer's dementia and the clinical precursor stage known as mild cognitive impairment. Nonpharmacologic interventions hold promise for enhancing functioning in these patients,...
Christopher J Poulos,Antony Bayer,Lauren Beaupre et al.
Christopher J Poulos et al.
As society grapples with an aging population and increasing prevalence of disability, "reablement" as a means of maximizing functional ability in older people is emerging as a potential strategy to help promote independence. Reablement offe...
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms [0.03%]
阿尔茨海默病的精神神经征兆和症状：新的治疗模式
Krista L Lanctôt,Joan Amatniek,Sonia Ancoli-Israel et al.
Krista L Lanctôt et al.
Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs a...
Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study [0.03%]
阿尔茨海默病患者维生素E和类胡萝卜素血清浓度改变的病例对照研究
Kathryn Mullan,Michael A Williams,Chris R Cardwell et al.
Kathryn Mullan et al.
Introduction: Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease (AD). We investigated associations between serum levels of lipophilic antioxidants and AD. ...
Lower brain and blood nutrient status in Alzheimer's disease: Results from meta-analyses [0.03%]
阿尔茨海默病患者脑部和血液营养状况较低：元分析结果
Martijn C de Wilde,Bruno Vellas,Elodie Girault et al.
Martijn C de Wilde et al.
Introduction: Alzheimer's disease (AD) patients are at risk of nutritional insufficiencies because of physiological and psychological factors. Recently, we showed the results of the meta-analyses indicating lower plasma l...
A randomized feasibility pilot trial of hearing treatment for reducing cognitive decline: Results from the Aging and Cognitive Health Evaluation in Elders Pilot Study [0.03%]
老年听觉治疗减少认知衰退可行性试点随机试验：ELDER保健和认知健康评估试点研究结果分析
Jennifer A Deal,Marilyn S Albert,Michelle Arnold et al.
Jennifer A Deal et al.
Introduction: Hearing loss (HL) is prevalent and independently related to cognitive decline and dementia. There has never been a randomized trial to test if HL treatment could reduce cognitive decline in older adults. ...
Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough? [0.03%]
抗β淀粉样蛋白抗体II期临床试验：够了没？
Michael Gold
Michael Gold
Efforts to develop new therapies to combat Alzheimer's disease suffer from extraordinarily high failure rates that make it difficult to justify continued investment in the field. Although there are a number of plausible explanations for thi...
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study [0.03%]
轻中度阿尔茨海默病的Ponezumab治疗：随机II期PET-Pib研究
Jaren W Landen,Niels Andreasen,Carol L Cronenberger et al.
Jaren W Landen et al.
Introduction: The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzhe...